References

cardiotomsk

Сибирский журнал клинической и экспериментальной медицины

Siberian Journal of Clinical and Experimental Medicine

2713-29272713-265X

TSU publishing

10.29001/2073-8552-2014-29-4-6-12

cardiotomsk-119

Research Article

ОБЗОРЫ И ЛЕКЦИИ

REVIEWS AND LECTURES

Нагрузочные дозы статинов для предупреждения повреждения миокарда при плановых эндоваскулярных вмешательствах по поводу стабильной ишемической болезни сердца (обзор литературы)

Loading doses of statins for prevention of pci-related myocardial injyry in patients with stable coronary heart disease: a literature review

Вершинина

Елена Олеговна

Vershinina

E. O.

oliver@cardio.tsu.ru

Сальникова

Елена Сергеевна

Salnikova

E. S.

elena.salnikova.mp@mail.ru

Репин

Алексей Николаевич

Repin

A. N.

ran 12@mail.ru

Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт кардиологии"РоссияFederal State Budgetary Scientific Institution "Research Institute for Cardiology"Russian Federation

2014

06092016

294612

2016

Вершинина Е.О., Сальникова Е.С., Репин А.Н.

Vershinina E.O., Salnikova E.S., Repin A.N.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://www.sibjcem.ru/jour/article/view/119

Многими авторами было продемонстрировано, что после чрескожного коронарного вмешательства происходит увеличение уровня сердечных биомаркеров, что свидетельствует о гибели кардиомиоцитов и некрозе миокарда. В последнее время были опубликованы исследования, которые показали эффективность статинов для профилактики этих событий вследствие наличия у них плейотропных свойств. В обзоре представлены результаты основных исследований использования нагрузочных доз сильнодействующих статинов - аторвастатина (ARMIDA, ARMIDA-RECAPTURE, NAPLES II и др.) и розувастатина (ROMA, ROMA II и др.) - для предупреждения перипроцедурного повреждения миокарда у пациентов со стабильной ишемической болезнью сердца (ИБС). Приведенные данные поддерживают потребность в более частом назначении высоких доз статинов для всех пациентов, направленных на плановое чрескожное коронарное вмешательство (ЧКВ) по поводу стабильной стенокардии, в том числе не получавших ранее статины, а также необходимость перезагрузки статинами перед ЧКВ у пациентов, уже длительно их принимающих.

Many authors showed that the levels of cardiac biomarkers suggestive of death of cardiomyocytes and necrosis of the myocardium increased after percutaneous coronary intervention. Recent studies demonstrated the efficacy of statins for the prevention of these events, due to the presence of pleiotropic properties. The review presents the main studies regarding the use of loading doses of potent statins: atorvastatin (ARMIDA, ARMIDA-RECAPTURE, NAPLES II et al.) and rosuvastatin (ROMA, ROMA II et al.) for the prevention of periprocedural myocardial damage in patients with stable coronary artery disease. These data support the need for more frequent administration of high doses of statins for all patients referred for elective PCI for stable angina, including naive statins, as well as the need for reloading statins before PCI in patients already receiving them long-term.

ИБСстабильная стенокардиястентирование коронарных артерийстатиныперипроцедурное повреждение миокардаcoronary artery diseasestable anginacoronary artery stentingstatinsperiprocedural myocardial damage

References1

Бокерия Л.А., Алекян Б.Г. Рентгеноэндоваскулярная диагностика и лечение заболеваний сердца и сосудов в Российской Федерации. - М. : НЦССХ им. А.Н. Бакулева РАМН, 2012. - 148 с.

Вершинина Е.О., Репин А.Н., Рябова Т.Р. и др. Ближайшие и отдаленные результаты плановых эндоваскулярных вмешательств на коронарных артериях и влияние на них нарушений углеводного обмена // Сибирский медицинский журнал (Томск). - 2013. - Т. 28, № 4. - С. 28-35.

Диагностика и коррекция нарушений липидного обмена с целью профилактики и лечения атеросклероза. Российские рекомендации. 5-й пересмотр [Электронный ресурс] -М., 2012. - 48 с. - URL: http://cardioline.ru/index.php/rekomendatsii-noa.

Abdelmeguid A.E., Topol E.J., Whitlow P.L. et al. Significance of mild transient release of creatine-kinase MB fraction after percutaneous coronary interventions // Circulation. - 1996. -Vol. 94. - Р. 1528-1536.

Alcock R.F., Roy P., Adorini K. et al. Incidence and determinants of myocardial infarction following percutaneous coronary interventions according to the revised Joint Task Force definition of troponin T elevation // Int. J. Cardiol. - 2010. - No. 140. -P. 66-72.

Angelini A., Rubartelli P., Mistrorigo F. et al. Distal protection with a filter device during coronary stenting in patients with stable and unstable angina // Circulation. - 2004. - Vol. 110, No. 5. - Р. 515-521.

Banerjee S., Brilakis E.S. Embolic protection during saphenous vein graft interventions // J. Invasive Cardiol. - 2009. -No. 21(8). - Р. 415-417.

Bourcier T., Libby P. HMG CoA reductase inhibitors reduce plasminogen activator inhibitor-1 expression by human vascular smooth muscle and endothelial cells // Arterioscler. Vasc. Biol. - 2000. - No. 20. - Р.556-562.

Brener S.J., Ellis S.G., Schneider J. et al. Frequency and long-term impact of myonecrosis after coronary stenting // Eur. Heart J. -2002. - No. 23. - Р. 869-876.

Briguori C., Colombo A., Airoldi F. et al. Statin administration before percutaneous coronary intervention: impact on periprocedural myocardial infarction // Eur. Heart J. - 2004. -No. 25. - Р. 1822-1828.

Briguori C., Visconti G., Focaccio A. Novel Approches for Preventing or Limiting Events (NAPLES II) Trial // J. Am. Coll. Cardiol. - 2009. - No. 54. - Р. 2157-2163.

Califf R.M., Abdelmeguid A.E., Kunitz R.E. Myonecrosis after revascularization procedures // J. Am. Coll. Cardiol. - 1998. -No. 31. - Р. 241-251.

Cannon C.P. Revascularisation for everyone? // Eur. Heart J. - 2004. - No. 25. - Р. 1471-1472.

Cay S., Cagirci G., Sen N. Prevention of periprocedural myocardial injury using a single high loading dose of rosuvastatin // Cardiovasc. Drugs Ther. - 2010. - No. 24. - Р. 41-47.

Chan A.W., Bhatt D.L., Chew D.P. et al. Early and sustained survival benefit associated with statin therapy at the time of percutaneous coronary intervention // Circulation. - 2002. -Vol. 105. - Р. 691-696.

Chan A.W., Bhatt D.L., Chew D.P. et al. Relation of inflammation and benefit of statins after percutaneous intervention on frequency of periprocedural myocardial injury // Am. J. Cardiol. - 2004. - No. 94. - Р. 1363-1366.

Conclusion Expert Society of Cardiology of the Russian Federation, Russian National Society of Atherosclerosis, Russian Society cardiosomatic rehabilitation and secondary prevention to optimize statin therapy in clinical practice // Rational Pharmacother Card. - 2011. - No. 7(1). - Р. 107-109.

Davignon J. Beneficial cardiovascular pleiotropic effects of statins // Circulation. - 2004. - Vol. 109, No. 23, Suppl. 1. -P. 1139-1143.

Desmet W.J., Dens J., Coussement P. et al. Does adenosine prevent myocardial micronecrosis following percutaneous coronary intervention? The ADELINE pilot trial // Heart. - 2002. -No. 88. - Р. 293-295.

Di Sciascio G., Patti G., Pasceri V. et al. Efficacy of atorvastatin reload in patients on chronic statin therapy undergoing percutaneous coronary intervention // J. Am. Coll. Cardiol. -2009. - No. 54. - Р. 558-565.

Ellis S.G., Chew D., Chan A. et al. Death following creatine kinase-MB elevation after coronary intervention. Identification of an early risk period: importance of creatine kinase-MB level, completeness of revascularization, ventricular function and and probable benefit of statin therapy // Circulation. - 2002. -Vol. 106. - Р. 1205-1211.

Herrmann J., Lerman A., Baumgart D. et al. Preprocedural statin medication reduces the extent of periprocedural non-Q-wave myocardial infarction // Circulation. - 2002. - Vol. 106. -Р. 2180-2183.

Heusch G., Kleinbongard P., Bose D. et al. Coronary microembolization: from bedside to bench and back to bedside // Circulation. - 2009. - Vol. 120, No. 18. - Р. 1822-1836.

Ioannidis J.P.A., Karvouni E., Katritis D.G. Mortality risk conferred by small elevations of creatine kinase-MB isoenzyme after percutaneous intervention // J. Am. Coll. Cardiol. - 2003. -No. 42. - Р. 1406-1411.

Klein R.W., Kramer B.L., Howard E. et al. Incidence and clinical significance of transient creatine kinase elevations and the diagnosis of non-Q wave myocardial infarction associated with coronary angioplasty // J. Am. Coll. Cardiol. - 1991. - No. 17. -Р. 321-326.

Kong T.Q., Davidson C.J., Meyers S.N. et al. Prognostic implication of creatine kinase elevation following elective coronary artery intervention. Page 15 of 29 Catheterization and Cardiovascular Interventions Catheterization and Cardiovascular Interventions 15 // JAMA. - 1997. - No. 277. - Р. 461-466.

Kurz D.J., Naegeli B., Bertel O. A double-blind, randomized study of the effect of immediate intravenous nitroglycerin on the incidence of post-procedural chest pain and minor myocardial necrosis after elective coronary stenting // Am. Heart J. - 2000. - No. 139. - Р. 35-43.

Levine G.N., Bates E.R., Blankenship J.C. et al. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: a report of the American College of Cardiology Foundation / American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions // Circulation. - 2011. - Vol. 24. - P. 574-651.

Mensah K., Mocanu M.M., Yellon D.M. Failure to protect the myocardium against ischemia/reperfusion injury after chronic atorvastatin treatment is recaptured by acute atorvastatin treatment: a potential role for phosphatase and tensin homolog deleted on chromosome ten? // J. Am. Coll. Cardiol. - 2005. -No. 45. - Р. 1287-1291.

Merla R., Reddy N.K., Wang F.W. et al. Meta-analysis of published reports on the effect of statin treatment before percutaneous coronary intervention on peri-procedural myonecrosis // Am. J. Cardiol. - 2007. - No. 100. - Р. 770-776.

Mood G.R., Bavry A.A., Roukoz H. et al. Meta-analysis of the role of statin therapy in reducing myocardial infarction following elective percutaneous coronary intervention // Am. J. Cardiol. - 2007. - No. 100. - Р. 919-923.

Pasceri V., Patti G., Nusca A. et al. Randomized trial of atorvastatin for reduction of myocardial damage during coronary intervention: results from the ARMYDA (Atorvastatin for Reduction of MYocardial Damage during Angioplasty) study // Circulation. - 2004. - Vol. 110. - Р. 674-678.

Patti G., Cannon C.P., Murphy S.A. et al. Clinical benefit of statin pretreatment in patients undergoing percutaneous coronary intervention. A collaborative patient-level meta-analysis of randomized study // Circulation. - 2011. - Vol. 123. - Р. 1622-1632.

Prasad A., Herrmann J. Myocardial Infarction due to percutaneous coronary intervention // N. Eng. J. Med. - 2011. - No. 364. - Р. 453-464.

Ricciardi M.J., Wu E., Davidson C.J. et al. Visualization of discrete microinfarction after percutaneous coronary intervention associated with mild creatine kinase-MB elevation // Circulation. - 2001. - Vol. 103. - Р. 2780-2783.

Rosenson R.S., Tangney C.C. Antiatherothrombotic properties of statins: implication for cardiovascular event reduction // JAMA. - 1998. - No. 279. - Р. 1643-1650.

Sacks F.M., Pfeffer M.A., Moye L.A. et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels: cholesterol and recurrent events trial investigators // N. Engl. J. Med. - 1996. - No. 335. - Р. 1001-1009.

Sardella G., Conti G., Donahue M. et al. Rosuvastatin pretreatment in patients undergoing elective PCI to reduce the incidence of myocardial periprocedural necrosis: the ROMA trial // Catheter Cardiovasc. Interv. - 2013. - No. 81. - Р. 36-43.

Sardella G., Lucisano L., Mancone M. et al. Comparison of high reloading ROsuvastatin and Atorvastatin pretreatment in patients undergoing elective PCI to reduce the incidence of MyocArdial periprocedural necrosis. The ROMA II trial [Электронный ресурс] // Int. J. Cardiol. - Jul. 11 2013. - URL: http://dx.doi.org/10.1016/j.ijcard.2013.06.017.

Sattler K.J., Herrmann J., Yun S. et al. High-density lipoproteincholesterol reduces risk and extent of percutaneous coronary intervention-related myocardial infarction and improves longterm outcome in patients undergoing elective percutaneous coronary intervention // Eur. Heart J. - 2009. - No. 30(15). -Р. 1894-1902.

Saucedo J.F., Mehran R., Dangas G. et al. Long term clinical events following creatin kinase-myocardial band isoenzyme elevation after successful coronary stenting // J. Am. Coll. Cardiol. - 2000. - No. 35. - Р. 1134-1141.

Scandinavian Simvastatin Survival Study (4S): Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease // Lancet. - 1998. - No. 344. - Р. 1383-1389.

Testa L., Van Gaal W.J., Biondi Zoccai G.G. et al. Myocardial infarction after percutaneous coronary intervention: a metaanalysis of troponin elevation applying the new universal definition // QJM. - 2009. - No. 102. - P. 369-378.

The EPISTENT Investigators: Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade // Lancet. - 1998. - No. 352. - Р. 87-92.

Thygesen K., Alpert J.S., Jaffe A.S. et al. Joint ESC/ACCF/AHA/WHF Task Force for the universal definition of myocardial infarction. Third universal definition of myocardial infarction // Eur. Heart J. - 2012. - No. 33. - Р. 2551-2567.

Thygesen K., Alpert J.S., White H.D. et al. Universal definition of myocardial infarction. Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction // Circulation. - 2007. - Vol. 116, No. 22. - P. 2634-2653.

Veselka J., Prochazkova S., Duchnova R. et al. Pre-procedural statin therapy reduces the risk and extent of cardiac biomarkers release following percutaneous coronary intervention // Heart Vessels. - 2006. - No. 21. - Р. 146-151.

Wang F.W., Osman A., Otero J. et al. Distal myocardial protection during percutaneous coronary intervention with an intracoronary b-blocker // Circulation. - 2003. - No. 107. -Р. 2914-2919.

The authors declare that there are no conflicts of interest present.